Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia

14 Apr 2016

Abstract excerpt

Myelodysplastic syndromes (MDS) are genetically diverse malignancies with peripheral cytopenias, dysplastic hematopoiesis, and increased risk for acute myeloid leukemia (AML) transformation. Recent investigations indicate that somatic, myeloid-specific gene mutations refine clinical staging to alter estimates of overall survival (OS), and should be included in current risk stratification models.1 Hence, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Lymphoma Diagnosis and Treatment
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27081179
DOI: 10.3324/haematol.2016.143214

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemiaPMID 27081179Read ↗

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.Semantic proximity Read ↗

Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis.Semantic proximity Read ↗

TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis.Semantic proximity Read ↗

Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.Semantic proximity Read ↗

Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53.Semantic proximity Read ↗

High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome.Semantic proximity Read ↗

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.Semantic proximity Read ↗

Early identification of TP53 mutations and TP53 allelic state in myelodysplastic neoplasms and acute myeloid leukemia via point‐of‐care p53 immunohistochemistrySemantic proximity Read ↗

Comparison of TP53 mutations in myelodysplasia and acute leukemia suggests divergent roles in initiation and progressionSemantic proximity Read ↗

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).Semantic proximity Read ↗

Exploring p53 protein expression and its link to TP53 mutation in myelodysplasia-related malignancies-Interpretive challenges and potential field of applications.Semantic proximity Read ↗

TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo‐Moffitt study of 156 informative casesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.